Valuation: VolitionRx Limited

Market Cap 63.89L 55.37L 51.84L 47.3L 89L 61Cr 90.5L 6.08Cr 2.38Cr 31Cr 2.4Cr 2.35Cr 101.76Cr P/E 2026 *
-0.34x
P/E 2027 * -0.55x
Enterprise Value 63.89L 55.37L 51.84L 47.3L 89L 61Cr 90.5L 6.08Cr 2.38Cr 31Cr 2.4Cr 2.35Cr 101.76Cr EV / Sales 2026 *
2.58x
EV / Sales 2027 * 1.11x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
1 day-9.39%
1 week-12.13%
Current month-3.90%
1 month-46.92%
3 months-66.34%
6 months-84.60%
Current year-86.50%
1 week 0.66
Extreme 0.6633
0.91
1 month 0.66
Extreme 0.6633
1.41
Current year 0.66
Extreme 0.6633
7.73
1 year 0.66
Extreme 0.6633
15.1
3 years 0.66
Extreme 0.6633
27.6
5 years 0.66
Extreme 0.6633
82.8
10 years 0.66
Extreme 0.6633
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap.
17/03/26 Tax

Chief Technology Officer

5,310 0.0039%
17/03/26 Tax

Company Secretary

3,948 0.0029%
01/03/26
Concord International, Inc.
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-9.39%-12.13%-94.43%-97.19% 63.89L
+1.18%+5.19%+112.55%+309.92% 406.17Cr
+0.04%+0.01%+65.83%+84.56% 371.97Cr
-0.23%+46.90%+225.13%-9.28% 289.9Cr
+1.15%+1.04%+304.25%+434.61% 243.51Cr
+1.43%+8.61%-20.91%-31.40% 231.49Cr
+5.03%+5.54%+9.93% - 131.14Cr
+5.85%+21.91%+8.32%+40.30% 99Cr
-2.55%-7.70%+188.11%-42.60% 90Cr
+5.70%+10.16%-32.72%+0.34% 54Cr
Average +0.84%+16.86%+76.61%+76.58% 191.82Cr
Weighted average by Cap. +1.27%+23.38%+115.74%+141.74%

Financials

2026 *2027 *
Net sales 24.78L 21.47L 20.1L 18.34L 34.51L 24Cr 35.09L 2.36Cr 92.34L 12Cr 93.03L 91L 39Cr 57.33L 49.69L 46.51L 42.44L 79.86L 55Cr 81.21L 5.45Cr 2.14Cr 27Cr 2.15Cr 2.11Cr 91Cr
Net income -2.22Cr -1.92Cr -1.8Cr -1.64Cr -3.09Cr -211.77Cr -3.14Cr -21Cr -8.28Cr -106Cr -8.34Cr -8.15Cr -353.62Cr -1.96Cr -1.7Cr -1.59Cr -1.45Cr -2.73Cr -187.12Cr -2.78Cr -19Cr -7.31Cr -94Cr -7.37Cr -7.21Cr -312.47Cr
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
-
Date Price Change Volume
11/26/11 $0.6901 -10.03% 5,40,397
10/26/10 $0.7670 -1.07% 3,44,476
07/26/07 $0.7753 +1.21% 4,56,759
06/26/06 $0.7660 -3.65% 5,58,909
05/26/05 $0.7950 +1.22% 99,38,048
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.7670USD
Average target price
16.97USD
Spread / Average Target
+2,111.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock